Paradigm Biocapital Advisors LP Buys New Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Paradigm Biocapital Advisors LP acquired a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 276,439 shares of the biopharmaceutical company's stock, valued at approximately $9,084,000. Agios Pharmaceuticals comprises about 0.3% of Paradigm Biocapital Advisors LP's portfolio, making the stock its 28th largest position. Paradigm Biocapital Advisors LP owned 0.48% of Agios Pharmaceuticals at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in AGIO. Franklin Resources Inc. acquired a new position in Agios Pharmaceuticals in the third quarter valued at approximately $1,499,000. Contravisory Investment Management Inc. acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at approximately $222,000. Inspire Investing LLC lifted its holdings in Agios Pharmaceuticals by 34.2% in the fourth quarter. Inspire Investing LLC now owns 12,384 shares of the biopharmaceutical company's stock valued at $407,000 after acquiring an additional 3,156 shares during the last quarter. KBC Group NV lifted its holdings in Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock valued at $86,000 after acquiring an additional 611 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Agios Pharmaceuticals by 10.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 12,092 shares of the biopharmaceutical company's stock valued at $397,000 after acquiring an additional 1,150 shares during the last quarter.

Insider Transactions at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the company's stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the sale, the director now owns 149,220 shares of the company's stock, valued at approximately $3,864,798. This represents a 4.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.30% of the company's stock.

Agios Pharmaceuticals Stock Performance

Shares of Agios Pharmaceuticals stock traded up $0.92 during trading hours on Friday, reaching $29.18. 771,981 shares of the company were exchanged, compared to its average volume of 697,635. Agios Pharmaceuticals, Inc. has a 1 year low of $23.42 and a 1 year high of $62.58. The stock's fifty day moving average is $28.81 and its 200 day moving average is $36.69. The firm has a market cap of $1.69 billion, a PE ratio of 2.57 and a beta of 0.77.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The business had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.86 million. Research analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have commented on AGIO. HC Wainwright began coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 price target on the stock. Scotiabank decreased their price target on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research note on Friday, May 2nd. Finally, StockNews.com upgraded Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, May 10th. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $56.00.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.